Every 10-Q that ODYSSEY HEALTH INC (ODYY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ODYY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ODYY filings page.
Odyssey Health, Inc. reported a small quarterly profit but remains in a fragile financial position. For the quarter ended April 30, 2026, the company generated net income of $765,890, mainly from a $1.5M non‑cash gain on the change in fair value of derivative liabilities and an $85,369 gain from forgiven payables, while operations still lost money.
The business recorded no revenue for the nine months and focuses on developing medical devices such as CardioMap and the Save‑A‑Life choking rescue device. For the nine months ended April 30, 2026, it posted a net loss of $3.3M and an accumulated deficit of $66.1M.
Liquidity is tight: cash was only $297,806 with current liabilities of $10.1M, resulting in a working capital deficit of $9.75M. Management states there is substantial doubt about the company’s ability to continue as a going concern and is relying on high‑cost convertible debt, complex derivative structures, and related warrants from investors such as Mast Hill and LGH to fund operations.
Odyssey Health, Inc. reported a larger loss and ongoing financial strain for the quarter ended January 31, 2026. The company generated no revenue and posted a net loss of $3,601,623 for the quarter and $4,085,070 for the six-month period, significantly higher than a year earlier.
Cash improved to $616,327, but current assets of $721,304 were far below current liabilities of $11,317,123, resulting in a working capital deficit of $10,595,819. Total stockholders’ deficit widened to $10,595,819, with an accumulated deficit of $66,830,907.
Losses were driven mainly by financing costs of $2,572,655, interest expense of $412,429, and a $424,348 loss from changes in derivative liabilities tied to recent Mast Hill financing arrangements. Derivative liabilities reached $3,936,166, reflecting highly structured convertible debt and warrants.
Management disclosed substantial doubt about Odyssey’s ability to continue as a going concern, citing recurring losses, negative cash flows and dependence on additional capital. The company continues to develop its CardioMap and Save-A-Life devices and entered a new BreastCheck® sublicense, but has not yet obtained regulatory clearance or begun product sales.
Odyssey Health reported another loss-making quarter with no revenue as its medical devices remain in development. For the three months ended October 31, 2025, the company posted a net loss of $483,447, an improvement from $1,018,906 a year earlier, helped by lower general and administrative costs and a non-cash gain of $422,419 from revaluing a derivative liability.
Liquidity remains very weak. Cash was only $25,586 and current liabilities were $7,298,810, resulting in a working capital deficit and stockholders’ deficit of $7,155,188 as of October 31, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital.
To fund operations, Odyssey relies heavily on high-cost debt and convertible instruments, including promissory notes and securities purchase agreements with Mast Hill Fund L.P. and other investors, which carry double‑digit interest and equity conversion features. Subsequent to quarter-end, Odyssey added a $2,262,000 convertible maintenance note and a new Mast Hill facility with up to $25 million in principal, further increasing potential dilution while expanding access to funding. The company also signed a technology sub‑license for BreastCheck®, adding a third development-stage asset.